Quantcast

Latest imidazoles Stories

2011-06-06 20:02:00

A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds. The new research findings will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston. "Our research suggests that one fifth or one half of the recommended dose might be sufficient to decrease fracture risk," said Andrew...

2011-05-23 09:00:00

DEERFIELD, Ill., May 23, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc. U.S., (TGRD U.S.) today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD). In two phase 3 studies, azilsartan medoxomil combined in a fixed-dose with CLD lowered clinic systolic blood pressure (SBP) significantly more than the fixed-dose combination of olmesartan medoxomil plus hydrochlorothiazide...

2011-05-23 07:00:00

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Data evaluating the long-term efficacy and safety of olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide (OM/AML + HCTZ) in patients with hypertension aged <65 years and greater than or equal to 65 years, showed that the triple therapy at Week 52 was both well-tolerated and effective in maintaining the blood pressure reductions seen in the pivotal study regardless of age.(1) The pre-specified subgroup analysis results,...

2011-05-11 05:00:00

PARSIPPANY, N.J. and TOKYO, May 11, 2011 /PRNewswire/ -- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, a pre-marketing application for approval for a companion diagnostic test has been submitted in the U.S.; the test also will be registered in Europe. Vemurafenib is an oral,...

2011-02-24 18:05:00

THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(®) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVA's superiority compared to Zometa...

2011-02-22 15:05:00

THOUSAND OAKS, Calif., Feb. 22, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myeloma, which compared XGEVA(TM) (denosumab) to Zometa® (zoledronic acid) in preventing skeletal-related events (SREs). The study, which appeared today in the Journal of Clinical Oncology, found that...

2011-02-14 10:29:00

CHICAGO, Feb. 14, 2011 /PRNewswire/ -- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1) It is associated with side effects such as post-dose syndrome and osteonecrosis of the jaw. A new patented method from Dr. Ketan Desai enables the administration of Zoledronic acid in combination with another drug that relieves the side effects. (Logo:...

2011-02-02 18:52:07

MGH study finds losartan improves delivery of therapies in laboratory, animal models Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid...

2010-12-11 00:44:38

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. "The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient,"...

2010-12-10 15:34:00

THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA(TM) (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® (zoledronic acid). These results underscore the efficacy profile of XGEVA in preventing skeletal-related events (SREs) in patients with bone metastases from advanced breast...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.